Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenue:
Licensing fees	$ 173,453	$ 164,975	$ 488,545	$ 336,400
Peptide and consumer product sales	175,794	340,349	428,521	475,281
Consumer product sales to affiliated company	121,275	187,779	233,878	239,050
Total revenue	470,522	693,103	1,150,944	1,050,731
Cost of revenue:
Cost of peptide and consumer product sales	109,363	247,698	267,136	338,995
Cost of consumer product sales to affiliated company	55,094	104,995	106,852	134,525
Total cost of revenue	164,457	352,693	373,988	473,520
Gross profit	306,065	340,410	776,956	577,211
Operating expenses:
Research and development	87,942	90,747	175,027	315,910
Marketing and business development	269,645	244,018	572,751	448,455
General and administrative	329,235	374,889	713,811	716,681
Accounting, legal and professional fees	181,201	144,196	400,423	309,633
Depreciation and amortization	22,063	28,147	45,158	54,764
Total operating expenses	890,086	881,997	1,907,170	1,845,443
Loss from operations	(584,021)	(541,587)	(1,130,214)	(1,268,232)
Other income (expense):
Interest income	384	928	1,124	2,132
Amortization of debt issuance costs	(50,123)	0	(62,240)	0
Equity in loss of affiliated company	(29,942)	(59,065)	(47,590)	(51,073)
Change in fair value of option to purchase interest in affiliated company	(4,597)	(25,151)	(11,217)	(17,436)
Total other income (expense), net	(84,278)	(83,288)	(119,923)	(66,377)
Net loss and comprehensive loss	$ (668,299)	$ (624,875)	$ (1,250,137)	$ (1,334,609)
Basic and diluted net loss per share (in Dollars per share)	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.03)
Weighted average shares outstanding (in Shares)	49,720,255	49,720,255	49,720,255	49,720,255